相关实验视频

Updated: Sep 11, 2025

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles

Published on: January 22, 2015

粉纳米粒子平台用于口服输送sinigrin在结肠炎治疗中

Hazzel Joy Adra¹, Hanvit Cha², Moon Han Chang³

¹Department of Food Science and Biotechnology, Kyung Hee University, Yongin, Republic of Korea; Department of Food Technology, College of Education, University of Santo Tomas, Espana Blvd, Sampaloc, Manila 1008, Philippines.

Carbohydrate polymers

|August 16, 2025

概括

这项研究引入了一种新型的粉纳米颗粒传递系统用于sinigrin,增强其口服生物可用性和治疗性结肠炎 (UC) 的疗效. 该系统有效地准肠道,减少炎症并保持肠道屏障的完整性.

科学领域:

药理学药理学是指药理学的学科.
纳米技术纳米技术
胃肠病学胃肠病学

背景情况:

葡萄糖酸盐的Sinigrin显示出治疗性结肠炎 (UC) 的前景.
口服西尼格林受到快速胃清除和低生物利用度的限制.
需要有效的药物输送系统来增强sinigrin对UC的治疗潜力.

研究的目的:

开发一种基于粉纳米粒子 (SNP) 的新型输送系统,用于sinigrin.
为了提高sinigrin的稳定性,封装效率和受控释放特性.
在UC的临床前模型中评估sinigrin装载SNP系统的体内疗效.

主要方法:

锡尼格林通过一种锡尼格林-莱西丁复合物 (SNG-L@SNPs) 被封装成粉纳米粒子.
评估了封装效率和抗酸性降解的稳定性.
实验室释放研究是在模拟的肠道条件下进行的.
一种体内性结肠炎小鼠模型被用于评估治疗疗效.

主要成果:

SNG-L@SNPs系统表现出高封装效率和增强的稳定性.
在模拟的肠道条件下观察到受控释放的sinigrin.
在体内研究表明,有效的向和释放sinigrin在肠道,转化为酸 (AITC) 的微生物群.
SNG-L@SNPs显著缓解了UC诱导的病理表现.
通过减少氧化应激,紧密结节中断和肠上皮细胞的亡,治疗保持了肠道屏障的完整性.

结论:

开发的含有sinigrin的粉纳米粒子系统为增强口服输送sinigrin提供了一个有希望的策略.
这种有针对性和受控释放系统通过减轻炎症和保护肠道屏障,有效地管理性结肠炎.
这些发现支持这种纳米输送系统在UC的精确和持续治疗管理方面的潜力.

关键词:

封装封装是一种封装.这是口头传递.氧化应激是一种氧化应激.这就是Sinigrin.粉纳米粒子是什么意思性结肠炎是一种

更多相关视频

Author Spotlight: Development and Characterization of Eco-Friendly Lignin-Based Microparticles for Enhanced Delivery of Bioflavonoids

Author Spotlight: Development and Characterization of Eco-Friendly Lignin-Based Microparticles for Enhanced Delivery of Bioflavonoids

Published on: March 1, 2024

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

相关概念视频

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Factors Affecting Dissolution: Particle Size and Effective Surface Area

Factors Affecting Dissolution: Particle Size and Effective Surface Area

Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...